Therefore, immunologic checkpoint blockade with antibodies that target CTLA-4 and PD-1/PD-L1 seemed promising strategies that could improve the outcomes in GC and deserved more specific studies (Figure 1). This evidence concerns the gene CTLA4 and gastric cancer.